Eagle Health Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

Eagle Health Investments’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.5M	Hold	884,121	–	–	4.89%	9
2026 Q1	$18.5M	Buy	+884,121	New	+$19.9M	3.24%	14
2025 Q4	–	Sell	-697,000	Closed	-$21M	–	34
2025 Q3	$21M	Buy	697,000 +69,400	+11%	+$2.08M	5.5%	7
2025 Q2	$22.8M	Hold	627,600	–	–	5.63%	8
2025 Q1	$22.7M	Hold	627,600	–	–	5.9%	9
2024 Q4	$26.4M	Buy	627,600 +65,900	+12%	+$3.27M	6.47%	7
2024 Q3	$31.2M	Buy	561,700 +37,200	+7%	+$1.89M	5.91%	7
2024 Q2	$21.6M	Buy	524,500 +224,800	+75%	+$9.6M	3.78%	11
2024 Q1	$14M	Buy	+299,700	New	+$14.1M	2.6%	15

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Eagle Health Investments's RARE Position: Q2 2026 in Review

Eagle Health Investments held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 884,121 shares worth $29.5M. The position accounts for 4.89% of the portfolio, ranked #9.

Eagle Health Investments first reported a position in RARE in Q1 2024 and has held it in 9 quarters since. The position peaked at $31.2M in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Eagle Health Investments held 884,121 shares of Ultragenyx Pharmaceutical worth $29.5M as of Q2 2026.
Eagle Health Investments left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
Ultragenyx Pharmaceutical made up 4.89% of Eagle Health Investments's portfolio in Q2 2026, its #9 holding.
Eagle Health Investments first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and has held it in 9 quarters since.
Eagle Health Investments's Ultragenyx Pharmaceutical position peaked at $31.2M in Q3 2024.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Eagle Health Investments's 13F filing for Q2 2026, filed 10 Aug 2026.